COVID-19 in Tunisia (North Africa): IgG and IgG subclass antibody responses to SARS-CoV-2 according to disease severity
Author:
Benabdessalem ChaoukiORCID, Marzouki Soumaya, Hamouda Wafa Ben, Trabelsi Khaled, Boumaiza Mohamed, Hamouda Sonia Ben, Ouni Rym, Bchiri Soumaya, Chaaban Amani, Gdoura Meriem, Gorgi Yousr, Sfar Imen, Yalaoui Sadok, Khelil Jalila Ben, Hamzaoui Agnes, Abdallah Meya, Cherif Yosra, Petres StéphaneORCID, Pun Mok Chris KaORCID, Escriou NicolasORCID, Quesney Sébastien, Dellagi KoussayORCID, Bettaieb JiheneORCID, Rourou Samia, Barbouche Mohamed RidhaORCID, Ahmed Melika BenORCID
Abstract
SummaryCoronavirus disease 2019 (COVID-19) expresses a wide spectrum of disease severity. We investigated the profile of IgG and IgG subclass antibody responses to SARS– CoV-2 in Tunisian patients with COVID-19 according to disease severity (86 patients with severe disease and 63 with mild to moderate disease). Two in house developed ELISA with excellent performance were used to test for antibodies to the nucleocapsid (N) protein and the receptor-binding domain of the spike antigen (S-RBD) of SARS-CoV-2. IgG, IgG1 and IgG3 antibodies were significantly higher in patients with severe disease compared to non-severe disease. Antibodies to S-RBD or the N protein were dominated by IgG1 and IgG3 or IgG1/IgG3 and IgG2 subclasses respectively. In patients with severe disease, IgG antibodies ‘ appearance to S-RBD was delayed compared to the N protein. IgG subclass imbalance may reflect the pathophysiology of COVID-19 and may herald disease aggravation. This study brings information on the immune responses to SARS-CoV-2 in North African patients and completes the picture drawn on COVID-19 in different African populations and worldwide.
Publisher
Cold Spring Harbor Laboratory
Reference31 articles.
1. Head-to-Head Evaluation of Five Automated SARS-CoV-2 Serology Immunoassays in Various Prevalence Settings;Journal of Clinical Medicine,2021 2. A perspective on potential antibody-dependent enhancement of SARS-CoV-2;Nature,2020 3. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival;Immunity,2020 4. Boonyaratanakornkit J , Morishima C , Selke S , Zamora D , McGuffin S , Shapiro AE , Campbell VL , McClurkan CL , Jing L , Gross R , Liang J , Postnikova E , Mazur S , Lukin VV , Chaudhary A , Das MK , Fink SL , Bryan A , Greninger AL , Jerome KR , Holbrook MR , Gernsheimer TB , Wener MH , Wald A , Koelle DM Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. The Journal of Clinical Investigation 131: e144930. https://doi.org/10.1172/JCI144930 5. Proinflammatory IgG Fc structures in patients with severe COVID-19
|
|